Biotechnology AssetsXMAD:BST 22 Median PS Value is €0.32 as of Jul. 11, 2026, which is 100% below its 10-year median of 0.66. GuruFocus rates XMAD:BST with a GF Score™ of 22/100 and a GF Value™ of €0.30 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 278 Biotechnology companies, Biotechnology Assets ranks worse than 51.8% on this metric.
This valuation method assumes that the stock valuation will revert to its historical (10-Year) median in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
The historical rank and industry rank for Biotechnology Assets's Median PS Value or its related term are showing as below:
XMAD:BST'
s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.56 Med: 0.66 Max: 1.17
Current: 0.66
During the past 13 years, the highest Price to Median PS Value of Biotechnology Assets was 1.17. The lowest was 0.56. And the median was 0.66.
XMAD:BST's Price-to-Median-PS-Value is ranked worse than 51.8% of 278
companies
in the Biotechnology industry
Industry Median: 0.645
vs XMAD:BST: 0.66
Biotechnology Assets (XMAD:BST) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio
is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
Biotechnology Assets's Price to Median PS Value for today is calculated as
Price to Median PS Value
=
Share Price
/
Median PS Value
=
0.211
/
0.32
=
0.66
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biotechnology Assets Median PS Value Related Terms
Biotechnology Assets Median PS Value Historical Data
* Premium members only.
The historical data trend for Biotechnology Assets's Median PS Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XMAD:BST vs VRTX, REGN, ALNY: Median PS Value Comparison
For the Biotechnology subindustry, Biotechnology Assets's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biotechnology Assets Price-to-Median-PS-Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Biotechnology Assets's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where Biotechnology Assets's Price-to-Median-PS-Value falls into.
10-Year Median PS Ratio is 7.4419.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Biotechnology Assets's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was €0.043.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biotechnology Assets (XMAD:BST) has a Median PS Value of €0.32 as of Jul. 11, 2026. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Biotechnology Assets and its competitors. This is 52% below median its historical median of 0.66. Over the past decade, Biotechnology Assets' Median PS Value has ranged from 0.56 to 1.17. According to the industry distribution chart, Biotechnology Assets ranks #144 out of 278 companies in the Biotechnology industry, placing it in the top 51.8%.
Is Biotechnology Assets' Median PS Value too high?
Biotechnology Assets' current Median PS Value of €0.32 is 52% below median its 10-year median of 0.66. Over the past 10 years, this metric has ranged from a low of 0.56 to a high of 1.17. Based on the distribution chart, Biotechnology Assets ranks #144 out of 278 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Biotechnology Assets has a GF Score™ of 22/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Biotechnology Assets' Median PS Value compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Biotechnology Assets ranks #144 out of 278 companies for Median PS Value. This places Biotechnology Assets in the lower half of its industry. The industry median Median PS Value is 0.65. Historically, Biotechnology Assets' own Median PS Value has ranged from 0.56 to 1.17 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Median PS Value for a Biotechnology company?
The median Median PS Value among Biotechnology companies is 0.65, based on 278 companies in the industry. Companies in the top quartile (top 25%) have a Median PS Value significantly above this median, while those in the bottom quartile fall well below. However, Median PS Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Median PS Value mean?
A high Median PS Value can signal that a stock is expensive relative to its fundamentals. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Biotechnology Assets and its competitors. For the Biotechnology industry, the median Median PS Value is 0.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Biotechnology Assets's current Median PS Value is €0.32, which is 52% below median its own 10-year median of 0.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biotechnology Assets stock overvalued right now?
Based on GuruFocus' analysis, Biotechnology Assets (XMAD:BST) is currently considered Possible Value Trap. The stock's GF Value™ is €0.30, compared to a current price of €0.21 — trading 29.7% below its estimated fair value. The current Median PS Value is €0.32, which is 52% below median its 10-year median of 0.66. Biotechnology Assets' overall GF Score™ is 22/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Median PS Value calculated?
Median PS Value is calculated from a company's financial statements. For Biotechnology Assets (XMAD:BST), the current Median PS Value is €0.32 as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Biotechnology Assets (XMAD:BST) Overvalued in 2026?
Based on GuruFocus' analysis, Biotechnology Assets stock appears to be undervalued.
The current stock price of €0.21 is trading 29.7% below its estimated GF Value™ of €0.30.
GuruFocus considers Biotechnology Assets to be Possible Value Trap.
Key valuation signals for XMAD:BST:
Median PS Value: €0.32 (52% below median its 10-year median of 0.66)
GF Value™: €0.30 vs. price of €0.21 (29.7% below fair value)
No single metric tells the full story. See the XMAD:BST stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Biotechnology Assets SA is a clinical-stage biopharmaceutical company developing and producing biological products for the pharmaceutical and veterinarian sectors. It specializes in the prevention and treatment of niche diseases, such as orphan disease, antigens for new-generation vaccines, feed additives, and probiotics. Adl Bionatur offers a portfolio of non-therapeutic and therapeutic products to tier 1 and tier 2 animal health companies. The company's pipeline products include BNT006, BNT007, BNT010, and others.
22GF Score
Get the complete analysis for XMAD:BST
Median PS Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XMAD:BST has been successfully added to your 
